Navigation Links
Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
Date:2/16/2011

HCl is ongoing and patients are being enrolled at 36 investigational sites worldwide.  A majority of the planned 60 subjects have been enrolled in the study. The Company expects to complete enrollment in the first half of 2011 and to report top line results from this study in the second half of 2011.

Amicus and GSK intend to commence an additional Phase 3 study (Study 012) in the first quarter of 2011. Study 012 will be an 18-month, randomized, open-label study comparing migalastat HCl to enzyme replacement therapy (ERT) in approximately 60 subjects. The primary outcome of efficacy will be renal function as measured by glomerular filtration rate (GFR).

About Fabry DiseaseFabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A (alpha-Gal A). The role of alpha-Gal A within the body is to break down a complex lipid called globotriaosylceramide (GL-3). Reduced or absent levels of alpha-Gal A activity leads to the accumulation of GL-3 in the affected tissues, including the central nervous system, heart, kidneys, and skin. This accumulation of GL-3 is believed to cause the various symptoms of Fabry disease, including pain, kidney failure, and increased risk of heart attack and stroke.

It is currently estimated that Fabry disease affects approximately 5,000 to 10,000 people worldwide.

About Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases.  The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease. 

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
10. Amicus Therapeutics Announces Change to Board of Directors
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held ... the three years through 2014. Being named to the Inc. 5000 list designates a ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated ...
(Date:8/26/2015)... KS (PRWEB) , ... August 26, 2015 , ... ... Biologic Solutions, announces today that a second US laboratory is to open in ... accordance with the continued partnership and long-term growth of research and development through ...
(Date:8/26/2015)... -- The Diabetes Research Institute (DRI), a Center of ... of Medicine, announced today that the first patient ... first time a novel transplant technique for insulin-producing ... I/II study builds upon decades of progress in ... step toward the development of the DRI BioHub, ...
(Date:8/26/2015)... China Cord Blood Corporation (NYSE: CO ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has been informed that Magnum Opus ... by Mr. Yuen Kam, chairman of the board of ... (the "Shares") of  Excellent China Healthcare Investment Limited ("KKR ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... dr. Stuart Parkin as its first ,distinguished professor, ever. Parkin ... of the IBM Almaden Research Center in the USA. Earlier ... Parkin is an expert in the field of spintronics. , ... international top professor to be appointed to this position for ...
... IDIX ) announced today that it will report,its ... Thursday, October,30, 2008 after the U.S. financial markets close., ... release, Idenix,management will host a conference call at 4:30 ... company,s financial results for the third quarter,of 2008 and ...
... Our Children Foundation,a nonprofit charitable foundation dedicated to ... Administration (FDA) has approved the Orphan,Drug Designation of ... Sarcoma cancer. The efforts to develop this drug ... in private industry and at two,universities., Orphan ...
Cached Biology Technology:FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children 2
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s touch ... 2015 that relate to sales of FPC1155 for this smartphone model ... for 2015. Jörgen Lantto, CEO of FPC, comments: " ... manufacturer in China and we are proud ... for Z1 , its first ...
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Something,s up with the weather in Namibia, say geoscientists ... Paul Bierman of the University of Vermont in Burlington, Vt. ... the western mountains and coastal plain of this sparsely populated ... where the stream beds are sand and the "lakes" are ...
... New research aimed at controlling the transmission of diseases ... made possible by grants from a collaboration among U.S. ... of the factors affecting disease transmission, the projects will ... Funding is from the U.S. National Science Foundation (NSF) ...
... 2011 Science in Society Journalism Awards, sponsored by the National ... Book category, Maryn McKenna for her book Superbug: The Fatal ... Reporting category, Katy Butler for her New York Times Magazine ... Reporting for a Local or Regional Audience category, Barbara Moran ...
Cached Biology News:Something odd is happening with Namibia's weather 2Something odd is happening with Namibia's weather 3Investigating the spread of infectious diseases with NSF, NIH, UK funding 2Investigating the spread of infectious diseases with NSF, NIH, UK funding 3Investigating the spread of infectious diseases with NSF, NIH, UK funding 4Investigating the spread of infectious diseases with NSF, NIH, UK funding 52011 Science in Society Awards announced 22011 Science in Society Awards announced 3
... matrix for the extraction of unwanted ... other macromolecules, Applications: ,Reducing octyl glucoside ... interaction of pure β-adrenergic receptor and ... SDS in 6 M urea/0.05 mM ...
... cells form from a hematopoietic stem cells ... to the bone surface and lowering the ... around 4.5. The bone mineral is then ... and function is controlled primarily by Macrophage ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... Service includes 1. Scanning of gel(s) ... High-sensitive tryptic in-gel digestion and peptide ... MALDI-MS 5. Acquisition of PMF (Peptide ... ultraflex TOF/TOF) 6. Acquisition of PFF ...
Biology Products: